GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » vTv Therapeutics Inc (NAS:VTVT) » Definitions » Revenue per Share

VTVT (vTv Therapeutics) Revenue per Share : $0.24 (TTM As of Dec. 2024)


View and export this data going back to 2015. Start your Free Trial

What is vTv Therapeutics Revenue per Share?

vTv Therapeutics's revenue per share for the three months ended in Dec. 2024 was $0.00. vTv Therapeutics's revenue per share for the trailing twelve months (TTM) ended in Dec. 2024 was $0.24.

Warning Sign:

vTv Therapeutics Inc revenue per share has been in decline over the past 3 years.

During the past 3 years, the average Revenue Per Share Growth Rate was -59.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.

The historical rank and industry rank for vTv Therapeutics's Revenue per Share or its related term are showing as below:

VTVT' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -60   Med: -1.4   Max: 151.7
Current: -59

During the past 12 years, vTv Therapeutics's highest 3-Year average Revenue Per Share Growth Rate was 151.70% per year. The lowest was -60.00% per year. And the median was -1.40% per year.

VTVT's 3-Year Revenue Growth Rate is ranked worse than
93.35% of 782 companies
in the Biotechnology industry
Industry Median: 1.05 vs VTVT: -59.00

vTv Therapeutics Revenue per Share Historical Data

The historical data trend for vTv Therapeutics's Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

vTv Therapeutics Revenue per Share Chart

vTv Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.45 2.56 1.05 - 0.18

vTv Therapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 0.24 - - -

Competitive Comparison of vTv Therapeutics's Revenue per Share

For the Biotechnology subindustry, vTv Therapeutics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


vTv Therapeutics's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, vTv Therapeutics's PS Ratio distribution charts can be found below:

* The bar in red indicates where vTv Therapeutics's PS Ratio falls into.


;
;

vTv Therapeutics Revenue per Share Calculation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

vTv Therapeutics's Revenue Per Share for the fiscal year that ended in Dec. 2024 is calculated as

Revenue Per Share (A: Dec. 2024 )=Revenue (A: Dec. 2024 )/Shares Outstanding (Diluted Average) (A: Dec. 2024 )
=1.017/5.771
=0.18

vTv Therapeutics's Revenue Per Share for the quarter that ended in Dec. 2024 is calculated as

Revenue Per Share (Q: Dec. 2024 )=Revenue (Q: Dec. 2024 )/Shares Outstanding (Diluted Average) (Q: Dec. 2024 )
=0.017/6.589
=0.00

Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.24

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


vTv Therapeutics  (NAS:VTVT) Revenue per Share Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:

Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


vTv Therapeutics Revenue per Share Related Terms

Thank you for viewing the detailed overview of vTv Therapeutics's Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


vTv Therapeutics Business Description

Traded in Other Exchanges
Address
3980 Premier Drive, Suite 310, High Point, NC, USA, 27265
vTv Therapeutics Inc is a clinical stage biopharmaceutical company focused on the development of orally administered treatments for metabolic and inflammatory diseases to minimize their long-term complications and improve the lives of patients. Its product pipeline include TTP399, TTP273, HPP737, HPP593, Azeliragon, HPP971, HPP3033, and TTP-RA.
Executives
Paul J Sekhri director, officer: President and CEO C/O VEEVA SYSTEMS INC., 4637 CHABOT DRIVE, SUITE 210, PLEASANTON CA 94588
Steven L. Tuch officer: Chief Financial Officer C/O VTV THERAPEUTICS INC., 3980 PREMIER DRIVE, HIGH POINT NC 27265
John A Fry director C/O DELAWARE INVESTMENTS, 2005 MARKET ST. 34TH FL., PHILADELPHIA PA 19103
Jonathan Isaacsohn director C/O VTV THERAPEUTICS INC., 3980 PREMIER DRIVE, HIGH POINT NC 27265
Fahed Al-marzooqi director AL KHATEM TOWER, ABU DHABI GLOBAL MARKET, ABU DHABI C0 00000
Keith R. Harris director C/O MEIRAGTX - US, 430 EAST 29TH STREET, 10TH FLOOR, NEW YORK NY 10016
Hersh Kozlov director WOLF BLOCK SCHORR & SOLIS, 1940 RTE 70 E, CHERRY HILL NJ 08003
Howard L. Weiner director 4170 MENDENHALL OAKS PKWY, HIGH POINT NC 27265
Chandresh Harjivan director C/O VTV THERAPEUTICS INC., 3980 PREMIER DRIVE, HIGH POINT NC 27265
Al-nahyan Tahnoon Bin Zayed S. 10 percent owner OFFICE 2458, FLOOR 24, AL-SILA TOWER, ABU DHABI C0 00000
G42 Investments Ai Holdings Rsc Ltd. director, 10 percent owner OFFICE 801, FLOOR 8, AL KHATEM TOWER, ABU DHABI C0 00000
Barry K. Brown officer: Chief Accounting Officer C/O VTV THERAPEUTICS INC., 3980 PREMIER DRIVE, HIGH POINT NC 27265
Rich S. Nelson director, officer: Acting Chief Executive Officer C/O VTV THERAPEUTICS INC., 3980 PREMIER DRIVE, HIGH POINT NC 27265
Ronald O Perelman 10 percent owner 35 EAST 62ND STREET, NEW YORK NY 10021
Deepa Prasad director, officer: President and CEO C/O VTV THERAPEUTICS INC., 3980 PREMIER DRIVE, SUITE 310, HIGH POINT NC 27265

vTv Therapeutics Headlines

From GuruFocus